Oculogyric Crisis Phenotype of Levodopa-Induced Ocular Dyskinesia.
作者信息
Olszewska Diana A, Shetty Rajesh, Geetha Thenral S, Ramprasad Vedam L, Lang Anthony E, Kukkle Prashanth Lingappa
机构信息
Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital Toronto Ontario Canada.
First Neuro Hospital Mangalore India.
出版信息
Mov Disord Clin Pract. 2022 Feb 10;9(3):390-393. doi: 10.1002/mdc3.13416. eCollection 2022 Apr.
Abstract
摘要
相似文献
1
Oculogyric Crisis Phenotype of Levodopa-Induced Ocular Dyskinesia.
Mov Disord Clin Pract. 2022 Feb 10;9(3):390-393. doi: 10.1002/mdc3.13416. eCollection 2022 Apr.
2
Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
J Neurol. 2016 May;263(5):888-894. doi: 10.1007/s00415-016-8075-6. Epub 2016 Mar 10.
3
[A drug induced deviation of the eyes: the oculogyric crisis].
Ned Tijdschr Geneeskd. 2021 Nov 30;165:D5988.
4
Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Neurol Res. 2014 Sep;36(9):841-6. doi: 10.1179/1743132814Y.0000000339. Epub 2014 Mar 7.
5
Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
Mov Disord. 1998 Jul;13(4):731-4. doi: 10.1002/mds.870130421.
6
The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Neurosci Lett. 2013 Nov 27;556:109-12. doi: 10.1016/j.neulet.2013.10.018. Epub 2013 Oct 14.
7
White matter alterations in Parkinson's disease with levodopa-induced dyskinesia.
Parkinsonism Relat Disord. 2021 Sep;90:8-14. doi: 10.1016/j.parkreldis.2021.07.021. Epub 2021 Jul 24.
8
Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
CNS Drugs. 2018 Oct;32(10):971-979. doi: 10.1007/s40263-018-0549-x.
9
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Mov Disord. 2015 May;30(6):788-95. doi: 10.1002/mds.26159. Epub 2015 Feb 4.
10
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
Mov Disord. 2017 Jun;32(6):893-903. doi: 10.1002/mds.26976. Epub 2017 Mar 30.
引用本文的文献
1
Non-nystagmus hyperkinetic eye movement disorders.
Neurol Sci. 2025 Mar 13. doi: 10.1007/s10072-024-07873-2.
本文引用的文献
1
Levodopa-Induced Ocular Dyskinesia in an Early-Onset Parkinson Disease Patient With GBA Mutation.
Clin Neuropharmacol. 2021;44(6):201-204. doi: 10.1097/WNF.0000000000000484.
2
Teaching Video NeuroImages: Oculogyric crisis in treated Parkinson disease.
Neurology. 2018 Jan 16;90(3):e263. doi: 10.1212/WNL.0000000000004816.
3
Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment.
Mov Disord. 2017 Feb;32(2):193-202. doi: 10.1002/mds.26910.
4
Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia.
Parkinsonism Relat Disord. 2014 Feb;20(2):245-7. doi: 10.1016/j.parkreldis.2013.10.016. Epub 2013 Oct 23.
5
Levodopa-induced ocular dyskinesia in Parkinson's disease.
Eur J Neurol. 2007 Oct;14(10):1124-8. doi: 10.1111/j.1468-1331.2007.01919.x.
6
Levodopa-induced ocular dyskinesias in Parkinson's disease.
Mov Disord. 2002 Jan;17(1):186-7. doi: 10.1002/mds.10017.
7
Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
Mov Disord. 1998 Jul;13(4):731-4. doi: 10.1002/mds.870130421.
8
[A 51-year-old man with early onset parkinsonism].
No To Shinkei. 1995 Jun;47(6):603-12.
9
Ocular dyskinesias in patients with Parkinson's disease treated with levodopa.
Ann Neurol. 1977 Feb;1(2):167-71. doi: 10.1002/ana.410010211.
Zotero 插件